{"symbol": "ADVM", "name": "Adverum Biotechnologies, Inc.", "next_earnings_utc": 1590696000, "next_earnings_period_start_date_utc": 1577750400, "next_earnings_period_end_date_utc": 1585612800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 95000.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.27111, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 10, "analysts_sell": 0, "analysts_buy": 6, "analysts_outperform": 3, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "adverum.com", "year_founded": 2006, "street_address": "800 Saginaw Drive", "city": "Redwood City", "state": "CA", "zipcode": "94063", "country": "United States", "phone_number": "650 656 9323", "short_description": "Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases.", "long_description": "Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration and diabetic retinopathy; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five ophthalmic indications; Regeneron Pharmaceuticals, Inc.; and GenSight Biologics S.A. to develop gene therapy products to deliver certain therapeutic transgenes. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1629863557, "total_enterprise": 1496276557, "number_of_employees": 114, "outstanding_shares": 79973678, "eps": -1.00599, "diluted_eps": -1.00599, "earnings_from_cont_operations": -64486000, "gross_profit": -40169000, "cash": 166035000, "total_debt": 32448000, "total_revenue": 250000, "cash_from_operations": -49170000, "net_income": -64486000, "ebitda": -66972000, "year_low_stock_price": 4.96, "year_high_stock_price": 23.79, "stocktwits_watchlist_count": 3213, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/ADVM.png"}